Transthyretin Amyloidosis Treatment Market By Product Type (ATTR-CM, ATTR-PN), By Therapy (Targeted Therapy, Supportive Therapy), By Disease Type (Hereditary Amyloidosis, Wild-type Amyloidosis, Other), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Transthyretin Amyloidosis Treatment Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. By Lowering The Synthesis Of Misfolded Proteins, Rnai-Based Therapies Such As Onpattro (Patisiran) Are Improving ATTR Results.

3.2.2. Treatment Options Are Being Expanded By New Medications Such As Vutrisiran And Acoramidis, Which Exhibit Good Clinical Effectiveness.

3.2.3. The FDA's Clearance Of Vyndaqel (Tafamidis) And Acoramidis Is Fuelling Market Expansion And Competition.

3.3. Key industry pitfalls & challenges

3.3.1. The Cost Of Advanced ATTR Medicines, Such As Stabilisers And Rnai Therapies, Prevents Many Patients From Accessing Them.

3.3.2. ATTR Is Uncommon And Its Symptoms Might Overlap With Those Of Other Illnesses, It Is Frequently Underdiagnosed, Which Delays The Start Of Treatment.

3.3.3. The Market Introduction Of Innovative Treatments Is Slowed By Stringent Regulatory Regulations And Drawn-Out Approval Procedures.

3.4. Market Opportunities

3.4.1. Continuous Developments In Gene-Editing And RNA Interference Technologies Hold Promise For Longer-Lasting And More Powerful Therapies.

3.4.2. Adoption Of Treatments Is Increasing As A Result Of Earlier Identification Made Possible By Enhanced Testing Technologies And Growing Awareness Efforts.

3.4.3. New Market Possibilities Are Being Created By Government Efforts And The Expansion Of Healthcare Infrastructure In Emerging Nations.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Transthyretin Amyloidosis Treatment Market, Product Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Product Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. ATTR-PN (Transthyretin Amyloid Polyneuropathy)

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Transthyretin Amyloidosis Treatment Market, Therapy Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Therapy, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Targeted Therapy

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Supportive Therapy

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Transthyretin Amyloidosis Treatment Market, Disease Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Disease, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Hereditary Amyloidosis

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Wild-type Amyloidosis

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Other

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Transthyretin Amyloidosis Treatment Market, Distribution Channel Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Distribution, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals Pharmacy

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Retail Pharmacies

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Other

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Transthyretin Amyloidosis Treatment Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Product Type, 2025-2035

8.2.3. North America Market Revenue, By Therapy, 2025-2035

8.2.4. North America Market Revenue, By Disease, 2025-2035

8.2.5. North America Market Revenue, By Distribution, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Product Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Therapy, 2025-2035

8.2.6.3. U.S. Market Revenue, By Disease, 2025-2035

8.2.6.4. U.S. Market Revenue, By Distribution, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Product Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Therapy, 2025-2035

8.2.7.3. Canada Market Revenue, By Disease, 2025-2035

8.2.7.4. Canada Market Revenue, By Distribution, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Product Type, 2025-2035

8.3.3. Europe Market Revenue, By Therapy, 2025-2035

8.3.4. Europe Market Revenue, By Disease, 2025-2035

8.3.5. Europe Market Revenue, By Distribution, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Product Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Therapy, 2025-2035

8.3.6.3. Germany Market Revenue, By Disease, 2025-2035

8.3.6.4. Germany Market Revenue, By Distribution, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Product Type, 2025-2035

8.3.7.2. France Market Revenue, By Therapy, 2025-2035

8.3.7.3. France Market Revenue, By Disease, 2025-2035

8.3.7.4. France Market Revenue, By Distribution, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Product Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Therapy, 2025-2035

8.3.8.3. U.K. Market Revenue, By Disease, 2025-2035

8.3.8.4. U.K. Market Revenue, By Distribution, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Product Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Therapy, 2025-2035

8.3.9.3. Italy Market Revenue, By Disease, 2025-2035

8.3.9.4. Italy Market Revenue, By Distribution, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Product Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Therapy, 2025-2035

8.3.10.3. Spain Market Revenue, By Disease, 2025-2035

8.3.10.4. Spain Market Revenue, By Distribution, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Product Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Therapy, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Disease, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By Distribution, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Product Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Therapy, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Disease, 2025-2035

8.4.5. Asia Pacific Market Revenue, By Distribution, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Product Type, 2025-2035

8.4.6.2. China Market Revenue, By Therapy, 2025-2035

8.4.6.3. China Market Revenue, By Disease, 2025-2035

8.4.6.4. China Market Revenue, By Distribution, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Product Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Therapy, 2025-2035

8.4.7.3. Japan Market Revenue, By Disease, 2025-2035

8.4.7.4. Japan Market Revenue, By Distribution, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Product Type, 2025-2035

8.4.8.2. India Market Revenue, By Therapy, 2025-2035

8.4.8.3. India Market Revenue, By Disease, 2025-2035

8.4.8.4. India Market Revenue, By Distribution, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Product Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Therapy, 2025-2035

8.4.9.3. Australia Market Revenue, By Disease, 2025-2035

8.4.9.4. Australia Market Revenue, By Distribution, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Product Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Therapy, 2025-2035

8.4.10.3. South Korea Market Revenue, By Disease, 2025-2035

8.4.10.4. South Korea Market Revenue, By Distribution, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Product Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Therapy, 2025-2035

8.4.11.3. Singapore Market Revenue, By Disease, 2025-2035

8.4.11.4. Singapore Market Revenue, By Distribution, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Product Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Therapy, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Disease, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By Distribution, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Product Type, 2025-2035

8.5.3. Latin America Market Revenue, By Therapy, 2025-2035

8.5.4. Latin America Market Revenue, By Disease, 2025-2035

8.5.5. Latin America Market Revenue, By Distribution, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Product Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Therapy, 2025-2035

8.5.6.3. Brazil Market Revenue, By Disease, 2025-2035

8.5.6.4. Brazil Market Revenue, By Distribution, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Product Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Therapy, 2025-2035

8.5.7.3. Argentina Market Revenue, By Disease, 2025-2035

8.5.7.4. Argentina Market Revenue, By Distribution, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Product Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Therapy, 2025-2035

8.5.8.3. Mexico Market Revenue, By Disease, 2025-2035

8.5.8.4. Mexico Market Revenue, By Distribution, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Product Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Therapy, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Disease, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By Distribution, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Product Type, 2025-2035

8.6.3. MEA Market Revenue, By Therapy, 2025-2035

8.6.4. MEA Market Revenue, By Disease, 2025-2035

8.6.5. MEA Market Revenue, By Distribution, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Product Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Therapy, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Disease, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By Distribution, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Product Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Therapy, 2025-2035

8.6.7.3. South Africa Market Revenue, By Disease, 2025-2035

8.6.7.4. South Africa Market Revenue, By Distribution, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Product Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Therapy, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Disease, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By Distribution, 2025-2035

9. Company Profile

9.1. Alnylam Pharmaceuticals

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Bridgebio Pharma

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Pfizer

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Ionis Pharmaceuticals

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Astrazeneca

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Alexion Pharmaceutical

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Proliferan

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Enobio Pharma

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Moderna

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Intellia Therapeutics

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Regeneron Pharmaceuticals

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. SomaLogic

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Prothena Corporation

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Eidos Therapeutics

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Corina Therapeutics

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis